NCT00704587

Brief Summary

The purpose of this study is to investigate every possible applicability of flow cytometrical analysis in the intracellular detection of tumor-related material in activated macrophages in the broadest range of cancer types.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
520

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2006

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

June 23, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 25, 2008

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

April 6, 2016

Status Verified

April 1, 2016

Enrollment Period

8.6 years

First QC Date

June 23, 2008

Last Update Submit

April 5, 2016

Conditions

Cancer

Keywords

cancer occurencecancer recurrenceneo-adjuvant treatment response measurement

Outcome Measures

Primary Outcomes (1)

  • screening and followup

    2 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patients diagnosed or suspected of cancerous conditions in the broadest sense of the word

You may qualify if:

  • (Suspicion of) presence of cancer in the broadest sense of the word
  • Must be able to understand and sign written informed consent

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Atrium Medical Centre Parkstad

Heerlen, Limburg, 6401 PC, Netherlands

Location

Maastricht University Medical Centre

Maastricht, Limburg, 6202 AZ, Netherlands

Location

Biospecimen

Retention: SAMPLES WITH DNA

white cells tissue plasma serum

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Dennis Japink, MD

    Atrium Medical Centre Parkstad, Heerlen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
drs

Study Record Dates

First Submitted

June 23, 2008

First Posted

June 25, 2008

Study Start

November 1, 2006

Primary Completion

June 1, 2015

Study Completion

July 1, 2015

Last Updated

April 6, 2016

Record last verified: 2016-04

Locations

NL(2)